Cost-effectiveness of strict "get to goal" treatment directives in the treatment of younger patients with newly diagnosed type 2 diabetes mellitus (T2DM)

被引：0
|
作者：
Willis, M. [1 ]
Borg, S. [1 ]
Persson, U. [1 ]
Neslusan, C. [2 ]
机构：
[1] Swedish Inst Hlth Econ, IHE, Lund, Sweden
[2] Johnson & Johnson, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)64969-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A260 / A260
页数：1
相关论文
共 50 条
  • [41] ADHERENCE AND PERSISTENCE IN PATIENTS INITIATING TREATMENT WITH INJECTABLE THERAPIES FOR TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sicras-Mainar, A.
    Navarro, R.
    Ruiz, L.
    Morano, R.
    VALUE IN HEALTH, 2015, 18 (07) : A612 - A612
  • [42] Thrombogenicity of flowing blood is increased in patients with type 2 diabetes mellitus (T2DM) despite treatment with aspirin
    Natarajan, A
    Marshall, S
    Hanley, J
    Badimon, JJ
    Zaman, A
    HEART, 2005, 91 : A61 - A61
  • [43] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS SITAGLIPTIN AS THIRD-LINE THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) IN A CANADIAN SETTING
    Sabapathy, S.
    Neslusan, C.
    Yoong, K.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    VALUE IN HEALTH, 2015, 18 (03) : A61 - A61
  • [44] Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus
    Ward, A
    O'Brien, JA
    Salas, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (04) : 601 - 608
  • [45] COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN SPAIN
    Ramirez de Arellano, A.
    Brosa, M.
    Franch, J.
    Mauricio, D.
    Alvarez, C.
    Sanchez-Zamorano, M.
    De Rivas, B.
    VALUE IN HEALTH, 2010, 13 (07) : A292 - A292
  • [46] COST-EFFECTIVENESS ANALYSIS OF XIGDUO (EXTENDED-RELEASE DAPAGLIFLOZIN-METFORMIN TABLETS) FOR MANAGING TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS
    Bao, H.
    Liu, Q.
    Peng, X.
    Xuan, J.
    VALUE IN HEALTH, 2024, 27 (06) : S122 - S122
  • [47] DELAYED TREATMENT MODIFICATIONS FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH VERY POOR GLYCEMIC CONTROL
    Schwab, P.
    Saundankar, V
    Bouchard, J. R.
    Moretz, C.
    Baltz, J.
    VALUE IN HEALTH, 2014, 17 (03) : A264 - A264
  • [48] COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN RUSSIA
    Arinina, E. E.
    Rashyd, M.
    VALUE IN HEALTH, 2012, 15 (04) : A172 - A172
  • [49] THE ECONOMIC IMPORTANCE OF "METABOLIC MEMORY" IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SWEDEN
    Willis, M.
    He, J.
    Neslusan, C.
    Chicevic, E.
    VALUE IN HEALTH, 2010, 13 (07) : A291 - A291
  • [50] Real-World Treatment for Diabetic Nephropathy (DN) in Patients with Type 2 Diabetes Mellitus (T2DM)
    Chaudhari, Paresh
    Zhou, Zhou
    Yang, Hongbo
    Zhao, Jing
    Wu, Eric
    Seifeldin, Raafat
    DIABETES, 2016, 65 : A603 - A603
12345